跳至主要内容
临床试验/CTRI/2024/08/072420
CTRI/2024/08/072420尚未招募2 期

ebulisation of lyophilised platelet-rich plasma to improve compromised lung health in patients caused by a mild-moderate COVID-19 infection - a Phase I/II, a randomised, placebo controlled, blinded study. - NI

Stem RX Hospital and Research Center0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Individuals who experience respiratory symptoms directly as a result
  • of COVID-19 infection.
  • - Patients with chest X-ray findings of peripheral ground glass opacities
  • seen in the lower lobe and/or consolidation
  • - Patients with fibrotic areas in the lung field on chest X-ray/CT scan
  • Six-minute walk test distance less than 300 m
  • - Individuals with associated systemic illnesses such as diabetes mellitus,
  • renal disease, hypertension, liver disease, pulmonary disorders, among
  • - Individuals who can give informed consent

排除标准

  • 1. Terminally ill COVID-19 patients/Patients not responding to conventional treatment/Patients with rapidly-progressing infection
  • 2. Patients on OR those requiring ventilator support
  • 3. Presence of active malignancy
  • 4. Immunodeficient conditions
  • 5. Hypercoagulation conditions
  • 6. Any other associated medical condition requiring immediate attention
  • or uncontrolled status.
  • 7. 10.Patients who have recently undergone organ transplantation, heartpacemaker
  • implantation (within 6 months)
  • 8. Patients with other infectious/communicable disease.
  • 9. Pregnant and lactating women

研究者

发起方
Stem RX Hospital and Research Center

相似试验